Craig-Hallum Maintains Buy on Guardant Health, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Alex Nowark maintains a Buy rating on Guardant Health (NASDAQ:GH) and raises the price target from $28 to $37.
August 08, 2024 | 4:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Craig-Hallum analyst Alex Nowark maintains a Buy rating on Guardant Health and raises the price target from $28 to $37.
The raised price target and maintained Buy rating from Craig-Hallum are positive signals for investors, likely leading to increased investor confidence and potential short-term price appreciation for Guardant Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100